Semaglutide

Overview

What it is, in plain language

Semaglutide is a long-acting GLP-1 receptor agonist, marketed clinically under the brand names Ozempic (diabetes) and Wegovy (obesity). It is the established benchmark in the incretin class and the most-studied weight-management compound of the past five years.

In the AEON line, Semaglutide is positioned alongside Retatrutide as a research-context metabolic compound — Semaglutide for protocols where the GLP-1-only mechanism is preferred, Retatrutide for the triple-agonist research frontier. AEON Semaglutide is supplied for in-vitro research only and is not approved by the TGA for human use.

Semaglutide is the benchmark of the incretin class — the broadest evidence base and the slowest tolerated titration.

Mechanism

How it works

Activates the GLP-1 receptor, producing dose-dependent appetite suppression, delayed gastric emptying, increased insulin secretion, and glucose-dependent suppression of glucagon. Weekly dosing is enabled by structural modifications (a C18 fatty-acid chain) that bind albumin and extend half-life to approximately 7 days.

Research findings

What the literature shows

The clinical literature is extensive. Phase 3 trials report ~15% body-weight reduction at 68 weeks at the 2.4 mg/week dose (Wegovy STEP trial program), with consistent improvements in HbA1c, blood pressure, and cardiovascular risk markers.

The compound has the strongest real-world evidence base in its class. GI side-effects (nausea, fatigue) are dose-dependent across the entire titration ladder and the literature is unanimous that mandatory slow titration is the difference between tolerated and abandoned protocols.

Cycle & Handling

Protocol reference

Common research-grade reference figures. Not medical advice — every protocol must be reviewed against the latest published literature and your study design.

Cycle guidance

Semaglutide is not cycled like the regenerative peptides. Same continuous-use pattern as Retatrutide: titration phase (16–20 weeks), active phase (6–18 months at maximum tolerated dose), maintenance step-down. Hard discontinuation is associated with rebound and weight regain. Pauses, if required, are tapered, not stopped.

Reconstitution

2 mL BAC → 10 mg/mL. Draw 0.025 mL = 0.25 mg; 0.05 mL = 0.5 mg; 0.10 mL = 1 mg; 0.24 mL = 2.4 mg. Insulin syringes essential for the smaller doses.

Storage

Lyophilised vial: room temperature short-term, refrigerator long-term. Reconstituted: refrigerate; use within 28 days when reconstituted with bacteriostatic water.

FAQ